Natalizumab in Multiple Sclerosis Treatment: From Biological Effects to Immune Monitoring

Natalizumab in Multiple Sclerosis Treatment: From Biological Effects to Immune Monitoring

Multiple sclerosis is a chronic demyelinating disease of the central nervous system (CNS) with an autoimmune component. Among the recent disease-modifying treatments available, Natalizumab, a monoclonal antibody directed against the alpha chain of the VLA-4 integrin (CD49d), is a potent inhibitor of...

Full description

Bibliographic Details
Main Authors: Kathy Khoy, Delphine Mariotte, Gilles Defer, Gautier Petit, Olivier Toutirais, Brigitte Le Mauff
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-09-01
Series:Frontiers in Immunology
Subjects:
multiple sclerosis
natalizumab
biotherapy
drug modifying therapy
Mab therapy monitoring
Integrin
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2020.549842/full

Similar Items

Similar Items